A Pipeline Built With Purpose

Leading with science and compassion, our team focuses on building our pipeline to improve patients’ lives by developing new, life-changing treatments while maximizing the potential of our existing medicines.

Program
Potential Indication
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

KRYSTEXXA® (pegloticase)

Combination with Immunomodulation in Uncontrolled Gout*

Phase 4

A recombinant uricase enzyme that breaks down urate.

MIRROR RCT: Phase 4 trial* evaluating KRYSTEXXA with methotrexate to increase the complete response rate in patients with uncontrolled gout.

UPLIZNA® (inebilizumab-cdon)

Myasthenia Gravis

Phase 3

IgG4-Related Disease

Phase 3

Kidney Transplant Desensitization

Phase 2

A humanized, affinity-optimized, afucosylated IgG1 kappa (IgG1κ) monoclonal antibody (mAb) that binds to the B cell-specific surface antigen CD19.

MINT: Phase 3 trial evaluating UPLIZNA for improving outcomes in patients with myasthenia gravis.

IgG4-Related Disease: Phase 3 trial evaluating UPLIZNA for the prevention of flare in patients with IgG4-related disease.

Kidney Transplant Desensitization: Phase 2 trial evaluating UPLIZNA, HZN-4920 or both, in highly-sensitized patients waiting for a kidney transplant.

HZN-825

Diffuse Cutaneous Systemic Sclerosis

Phase 2

Idiopathic Pulmonary Fibrosis

Phase 2

A molecule that blocks lysophosphatidic acid receptor 1 (LPAR1), preventing gene activation. We are initiating a Phase 2b pivotal trial in diffuse cutaneous systemic sclerosis and a Phase 2b pivotal trial in interstitial lung disease.

HZN-4920

Sjögren’s Syndrome

Phase 2

Rheumatoid Arthritis

Phase 2

Kidney Transplant Rejection

Phase 2

A fusion protein binding CD40L on T cells, blocking their interaction with CD40-expressing B cells. We are conducting Phase 2 clinical trials in Sjögren’s syndrome, rheumatoid arthritis and kidney transplant rejection.

HZN-7734

Systemic Lupus Erythematosus

Phase 2

COVID-19 Acute Lung Injury

Phase 1

A monoclonal antibody against ILT7 that depletes certain dendritic cells. We are conducting a Phase 1 clinical trial in COVID-19 acute lung injury and plan to start a Phase 2 clinical trial in systemic lupus erythematosus.

TEPEZZA® (teprotumumab-trbw)

Subcutaneous Administration

Phase 1

Diffuse Cutaneous Systemic Sclerosis

Phase 1

A monoclonal antibody against insulin-like growth factor-1 receptor (IGF-1R).

Subcutaneous Administration: Phase 1 pharmacokinetic trial to explore subcutaneous administration of TEPEZZA.

Diffuse Cutaneous Systemic Sclerosis: Phase 1 trial exploring TEPEZZA in diffuse cutaneous systemic sclerosis.

HZN-1116

Autoimmune Diseases

Phase 1

We plan to start a Phase 1 trial in autoimmune diseases.

HZN-003

Next-Gen Uncontrolled Gout

Pre-clinical

We are conducting preclinical research with this molecule.

HZN-007

Next-Gen Uncontrolled Gout

Pre-clinical

We are conducting preclinical research with this molecule.

HemoShear

Novel Gout Targets

Pre-clinical

Horizon entered into an exclusive collaboration to discover novel gout targets, by combining HemoShear’s REVEAL-Tx platform with Horizon’s rheumatology development and commercialization expertise.


BRAND NAME (generic name)
Lorem ipsum dolor sit amet

BRAND NAME (generic name)
Lorem ipsum dolor sit amet

Moving On-Market Medicines Forward

Horizon is exploring the potential of its on-market medicines to identify paths for new treatment methods and improve patient outcomes.

A recombinant uricase enzyme that breaks down urate.

PROTECT: Phase 4 trial evaluating KRYSTEXXA to improve management of uncontrolled gout in kidney transplant patients.

AGILE: Phase 4 trial evaluating the impact of administering KRYSTEXXA over a shorter infusion duration in patients with uncontrolled gout who are receiving methotrexate.

FORWARD OL: Phase 4 trial evaluating monthly dosing of KRYSTEXXA with methotrexate in patients with uncontrolled gout.

Retreatment: Phase 4 trial evaluating KRYSTEXXA with methotrexate in patients who have previously failed KRYSTEXXA monotherapy.

A monoclonal antibody against insulin-like growth factor-1 receptor (IGF-1R).

Chronic Thyroid Eye Disease (TED): Phase 4 trial evaluating TEPEZZA in chronic TED to generate additional clinical data in this patient population.

Clinical Trials

Clinical trials are essential to the research and development process and play a vital role in helping physicians and investigators understand how an investigational medicine may safely and effectively treat a specific disease or condition.

For a comprehensive list of current clinical trials involving Horizon medicines, please visit: www.clinicaltrials.gov.

For more information about expanded access programs, read our Expanded Access Policy Statement.

This information was last updated on June 23, 2021.

C-HZN-00316-5